Cemiplimab
Modify Date: 2024-01-05 11:44:27
Cemiplimab structure
|
Common Name | Cemiplimab | ||
|---|---|---|---|---|
| CAS Number | 1801342-60-8 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of CemiplimabCemiplimab (Anti-Human PD-1) is a high-affinity programmed death receptor-1 (PD-1) monoclonal IgG4 antibody that blocks PD-1/PD-L1-mediated T-cell suppression. Cemiplimab is commonly used in squamous cell skin cancer research[1][2]. |
| Name | Cemiplimab |
|---|
| Description | Cemiplimab (Anti-Human PD-1) is a high-affinity programmed death receptor-1 (PD-1) monoclonal IgG4 antibody that blocks PD-1/PD-L1-mediated T-cell suppression. Cemiplimab is commonly used in squamous cell skin cancer research[1][2]. |
|---|---|
| Related Catalog | |
| In Vivo | Cemiplimab (i.p., 10 mg/kg, five injections within 2 weeks) can increased the proportion of effector T cells in tumors and dLNs to reduce tumor growth by combined immunotherapy with REGN3767 in MC38.Ova tumor mice model[2]. Animal Model: Female human PD-1×LAG-3 knockin mice (8-10 weeks) with MC38.Ova cells[2] Dosage: 10 mg/kg Administration: Intraperitoneal injection; five injections within 2 weeks Result: Partially inhibited the growth of MC38.Ova tumors and prolonged the survival of mice by administering alone. Significantly increased the proportion of CD4+ TILs in IFNγ and TNFα by combined immunotherapy with REGN3767. |
| References |
| Storage condition | 2-8°C |
|---|